The stock of pharmaceutical major Zydus Lifesciences is up about 10 per cent from its low towards the end of November, even after considering the correction seen in the past few sessions. Brokerages are positive on the stock, given traction for its key products in the US market, new limited-competition drug launches, regulatory clearance for the Moraiya facility and market share gains in the domestic market.
The near-term trigger has been the launch of the generic version of Trokendi in the US. The drug used in treating migraines has been launched by Zydus in three strengths with a market size of